Search our team at AdventHealth Research Institute
-
NCT05027971
Multi-center, open label, prospective study to document on-going post market safety and performance of Flexiva Pulse High Power Single-Use Laser Fibers.
This study is not currently enrolling.Research Area: Digestive Health and SurgeryMulti-center, open label, prospective study to document on-going post market safety and performance of Flexiva Pulse High Power Single-Use Laser Fibers.
-
Conservative Fluid Management in the First Week of Life Reduces the Risk of Prolonged Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants
This study is not currently enrolling.Research Area: Pediatric Research and Clinical TrialsResearch Location: Orlando, FloridaTo retrospectively collect and analyze the data to show that a change in practice at the Advent Health Orlando Neonatal Intensive Care Unit (NICU), implementing conservative fluid intake during the...
-
Optune Lua for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy
This study is not currently enrolling.Associated Conditions: Malignant Pleural MesotheliomaResearch Area: Clinical Cancer ResearchOptune Lua is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (“MPM”) to be used concurrently with pemetrexed and...
-
NCT05076838
An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO with Open-Label Safety Period in Pediatric Subjects with Epilepsy
This study is not currently enrolling.Associated Conditions: EpilepsyResearch Area: Clinical Neuroscience ResearchThis is a research study to evaluate the pharmacokinetics (PK), safety and tolerability after a single intranasal dose of VALTOCO (diazepam nasal spray), followed by a long-term safety period, where...
-
NCT05107856
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchThe purpose of this research study is to test the safety of PRT1419 at different dose levels to find out what effects, good and/or bad, PRT1419 has on you and your type of cancer. The information...
-
NCT04669899
Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
This study is not currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Clinical Cancer ResearchA medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening...
-
NCT04998747
A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)
This study is not currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Clinical Cancer ResearchParticipants who have have relapsed (returning) and refractory (stopped responding to treatment) multiple myeloma (RRMM) will be invited to take part in this study. This study is being done to learn...
-
NCT04935359
A randomized, three-arm, double-blind, placebo-controlled, phase III study, comparing NIS793 with or without spartalizumab in combination with gemcitabine and nab-paclitaxel versus matching placebos combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
This study is not currently enrolling.Associated Conditions: Pancreatic CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC. This study...
-
NCT04628481
GLADIATOR: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline.
This study is not currently enrolling.Associated Conditions: Diabetes-Drug StudyResearch Area: Translational Research for Metabolism and DiabetesResearch Location: Orlando, FloridaThe purpose of this study is to check and collect data of how the body absorbs, distributes and gets rid of the study drug in the blood during the first cycle of LDX0319 study treatment. These data...
-
Phase II Trial of Trilaciclib added to Chemotherapy plus Pembrolizumab in the First-line Treatment of patients with Advanced Non-Small Cell Lung Cancer.
This study is not currently enrolling.Associated Conditions: Lung CancerResearch Area: Clinical Cancer Research -
NCT04185363
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)
This study is not currently enrolling.Associated Conditions: Wilsons DiseaseResearch Area: Pediatric Research and Clinical TrialsResearch Location: Orlando, FloridaThe primary objective of the study is to evaluate the long-term safety and tolerability of maralixibat. Secondary objectives: To evaluate the long-term efficacy of maralixibat, including the...
-
NCT04403022
A Prospective, Multi-Center Investigation of the da Vinci SP Surgical System in Colorectal Procedures for Benign and Malignant Disease.
This study is not currently enrolling.Research Area: Digestive Health and SurgeryThe purpose of this study is to collect data to evaluate safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in colorectal procedures. These colorectal procedures...